Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
COAG Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG
Total Assets · Q2 FY2026 · quarter ended Jun 2026
Total assets of $467.78M in Q2 FY2026
Q2 FY2026 total assets was $467.78M.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 194.78M USD
- Year-over-year change
- —
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 194.78M | — |
Total Assets vs competitors
How COAG compares with its peers on the latest reported figures
- COAG's Jun 2026 total assets of $467.78M is the 4th highest of the 5 companies compared; the peer median is $617.47M.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $778.71M | +28.6% | +5.4% | |
IRONDisc Medicine, Inc. | Sep 2026 | $699.49M | +10.9% | +59.1% |
DMRADamora Therapeutics, Inc. | Mar 2026 | $535.44M | +3384.8% | +52.7% |
COAGHemab Therapeutics Holdings, Inc. Common Stock | Jun 2026 | $467.78M | — | — |
| Mar 2026 | $54.47M | -6.1% | -29.9% | |
| Peer median (excluding COAG) | $617.47M | +19.8% | +29.0% | |
Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
Intrinsic Alpha fair value
Locked
Current Price
$39.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.